Injection Site Irritation Completed Phase 4 Trials for Lidocaine (DB00281)

IndicationStatusPhase
DBCOND0063115 (Injection Site Irritation)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01824758Effect of Esmolol on Pain Due to RocuroniumSupportive Care
NCT02524743The Prevention of Pain Associated With Rocuronium InjectionTreatment